hodgkin’s lymphoma
Old CDF drug not recommended in initial NICE guidance due to lack of evidence
August 10, 2016Research and Development, Sales and Marketing Adcetris, Cancer Drugs Fund, NICE, Takeda, hodgkin's lymphoma
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Takeda’s Adectris (brentuximab vedotin), despite …
Latest content
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
